Cited by 93Parkinson's Disease Mechanisms and TreatmentsVirus-based gene therapy researchNerve injury and regeneration

Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct

Fjord-Larsen, Lone, Johansen, Jens Leander, Kusk, Philip, Tornøe, Jens, Grønborg, Mette, Rosenblad, Carl, Wahlberg, Lars U.·2005·Experimental Neurology

Abstract

Protein injection studies of the glial cell line derived neurotrophic factor (GDNF) family member Neurturin (NTN) have demonstrated neuroprotective effects on dopaminergic (DA) neurons, which are selectively lost during Parkinson's disease (PD). However, unlike GDNF, NTN has not previously been applied in PD models using an in vivo gene therapy approach. Difficulties with lentiviral gene delivery of wild type (wt) NTN led us to examine the role of the pre-pro-sequence, and to evaluate different NTN constructs in order to optimize gene therapy with NTN. Results from transfected cultured cells showed that wt NTN was poorly processed, and secreted as a pro-form. A similarly poor processing was found with a chimeric protein consisting of the pre-pro-part from GDNF and mature NTN. Moreover, we found that the biological activity of pro-NTN differs from mature NTN, as pro-NTN did not form a signaling complex with the tyrosine kinase receptor Ret and GFRalpha2 or GFRalpha1. Deletion of the pro-region resulted in significantly higher secretion of active NTN, which was further increased when substituting the wt NTN signal peptide with the immunoglobulin heavy-chain signal peptide (IgSP). The enhanced secretion of active mature NTN using the IgSP-NTN construct was reproduced in vivo in lentiviral-transduced rat striatal cells and, unlike wt NTN, enabled efficient neuroprotection of lesioned nigral DA neurons, similar to GDNF. An in vivo gene therapy approach with a modified NTN construc…

Integrity signals

Registry

Crossref · 10.1016/j.expneurol.2005.03.006

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • NRTN displays neuroprotection through enhancing dopaminergic neuronal survival and behavioural function in animal models.

    “NRTN displays neuroprotection through enhancing dopaminergic neuronal survival and behavioural function in animal models [73, 74], and adeno-associated virus serotype 2 (AAV-2) vector encoding the human NRTN gene (CERE120) has been developed to potentially provide clinical benefits in Parkinson’s disease [75].”

Cited by

Sorted by citations

Authors
Fjord-Larsen, L., Johansen, J. L., Kusk, P., Tornøe, J., Grønborg, M., Rosenblad, C., & Wahlberg, L. U.
Affiliations
NsGene (Denmark) (DK)
Corresponding author
Wahlberg, Lars U.
Venue
Experimental Neurology
Publisher
Elsevier BV
Published
2005-09
Volume
195
Issue
1
Pages
49-60
ISSN
0014-4886 (ISSN-L)
OpenAlex
W1998982801
Cited by
93
References
0
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 4 · 2014: 3 · 2013: 6 · 2012: 6
FWCI
5.18
Type
journal article
Language
en
Open access
closed
Locations
  • Experimental Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords
neurturin, Parkinson's disease, dopaminergic neurons, lentiviral gene therapy, neuroprotection, RET receptor, GDNF family, striatal cells, gene delivery
MeSH terms
Amphetamine, Analysis of Variance, Animals, Cell Count, Cell Line, Cloning, Molecular, Dopamine, Enzyme-Linked Immunosorbent Assay, Epithelial Cells, Female, Gene Expression Regulation, Genetic Vectors, Humans, Immunohistochemistry, Nerve Growth Factors, Neurons, Parkinson Disease, Secondary, Pigment Epithelium of Eye, Proto-Oncogene Proteins, Substantia Nigra, Transfection, Tyrosine 3-Monooxygenase, Blotting, Western, Genetic Therapy, Lentivirus, Oxidopamine, Rats, Sprague-Dawley, Gene Transfer Techniques, Neuroprotective Agents, Dopamine Uptake Inhibitors, Receptor Protein-Tyrosine Kinases, Conotoxins, Proto-Oncogene Proteins c-ret, Glial Cell Line-Derived Neurotrophic Factor Receptors, Neurturin, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review